COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
Abstract The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Rheumatology international - 42(2021), 1 vom: 15. Nov., Seite 23-29 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sen, Parikshit [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Crown 2021 |
|---|
| doi: |
10.1007/s00296-021-05046-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2077788550 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2077788550 | ||
| 003 | DE-627 | ||
| 005 | 20230507083843.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-021-05046-4 |2 doi | |
| 035 | |a (DE-627)OLC2077788550 | ||
| 035 | |a (DE-He213)s00296-021-05046-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Sen, Parikshit |e verfasserin |0 (orcid)0000-0002-1630-6026 |4 aut | |
| 245 | 1 | 0 | |a COVID-19 vaccination in autoimmune disease (COVAD) survey protocol |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Crown 2021 | ||
| 520 | |a Abstract The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a COVAD | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a Survey | |
| 700 | 1 | |a Gupta, Latika |0 (orcid)0000-0003-2753-2990 |4 aut | |
| 700 | 1 | |a Lilleker, James B. |0 (orcid)0000-0002-9230-4137 |4 aut | |
| 700 | 1 | |a Aggarwal, Vishwesh |0 (orcid)0000-0002-0986-8354 |4 aut | |
| 700 | 1 | |a Kardes, Sinan |0 (orcid)0000-0002-6311-8634 |4 aut | |
| 700 | 1 | |a Milchert, Marcin |0 (orcid)0000-0002-0943-8768 |4 aut | |
| 700 | 1 | |a Gheita, Tamer |0 (orcid)0000-0002-1155-9729 |4 aut | |
| 700 | 1 | |a Salim, Babur |0 (orcid)0000-0001-8430-9299 |4 aut | |
| 700 | 1 | |a Velikova, Tsvetelina |0 (orcid)0000-0002-0593-1272 |4 aut | |
| 700 | 1 | |a Gracia-Ramos, Abraham Edgar |0 (orcid)0000-0003-1842-2554 |4 aut | |
| 700 | 1 | |a Parodis, Ioannis |0 (orcid)0000-0002-4875-5395 |4 aut | |
| 700 | 1 | |a O’Callaghan, Albert Selva |0 (orcid)0000-0003-2823-9761 |4 aut | |
| 700 | 1 | |a Nikiphorou, Elena |0 (orcid)0000-0001-6847-3726 |4 aut | |
| 700 | 1 | |a Tan, Ai Lyn |0 (orcid)0000-0002-9158-7243 |4 aut | |
| 700 | 1 | |a Cavagna, Lorenzo |0 (orcid)0000-0003-3292-1528 |4 aut | |
| 700 | 1 | |a Saavedra, Miguel A. |0 (orcid)0000-0003-0687-9944 |4 aut | |
| 700 | 1 | |a Shinjo, Samuel Katsuyuki |0 (orcid)0000-0002-3682-4517 |4 aut | |
| 700 | 1 | |a Ziade, Nelly |0 (orcid)0000-0002-4479-7678 |4 aut | |
| 700 | 1 | |a Knitza, Johannes |0 (orcid)0000-0001-9695-0657 |4 aut | |
| 700 | 1 | |a Kuwana, Masataka |0 (orcid)0000-0001-8352-6136 |4 aut | |
| 700 | 1 | |a Cagnotto, Giovanni |0 (orcid)0000-0002-1682-8158 |4 aut | |
| 700 | 1 | |a Nune, Arvind |0 (orcid)0000-0002-3849-614X |4 aut | |
| 700 | 1 | |a Distler, Oliver |0 (orcid)0000-0002-0546-8310 |4 aut | |
| 700 | 1 | |a Chinoy, Hector |0 (orcid)0000-0001-6492-1288 |4 aut | |
| 700 | 1 | |a Aggarwal, Vikas |0 (orcid)0000-0002-2089-027X |4 aut | |
| 700 | 1 | |a Aggarwal, Rohit |0 (orcid)0000-0001-7531-8038 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 42(2021), 1 vom: 15. Nov., Seite 23-29 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:1 |g day:15 |g month:11 |g pages:23-29 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00296-021-05046-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 1 |b 15 |c 11 |h 23-29 | ||